Definitive Contract HHSN261201000045C
Award Date
9/24/10
Potential Completion Date
7/29/11
Potential Value
$199K
Federal Agency
National Cancer Institute
Awardee
Keystone Nano Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
State College, PA, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
18
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanoscale Corporation. The $831,900 contract is for the development of "functionalized bimagnetic core/shell Fe/Fe3O4 stealth nanoparticles" for the diagnosis and treatment of cancer. The contract includes two major subcontractors - Xenometrics, LLC, which will conduct toxicology testing, and the...
<p>This is a $299,813 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Hylapharm LLC, a self-certified small disadvantaged business, under the SBIR Program Phase I. The contract is for the development of "Targeted Nanoparticle Treatment for Breast Cancer Stem Cells." This contract has a Total Small Business set-aside designation. The contract has an ultimate completion date of September 17, 2016.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...
<p>This contract was awarded by the National Cancer Institute, a civilian agency, to Nanoparticle Biochem, Inc., a for-profit organization and manufacturer of goods. The $998,293.57 cost-plus-fixed-fee contract is for the development of in vivo compatible and readily injectable gold nanoconstructs for tumor therapy. The contract was set aside for a small business and has an ultimate completion date of August 26, 2015.</p>
This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of "MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY", which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...
<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
The U.S. government awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Evident Technologies, Inc., a small business located in Troy, NY. The $172,216.00 fixed-price contract is for the development of quantum dot nanotechnology to quantify marker expression in breast cancer. The contract was awarded on August 2, 2006 by a U.S. government agency, with a completion date of August 1, 2007. This SBIR Phase I contract is part of the agency's initiatives to support...
This is a Small Business Innovation Research (SBIR) Program Phase I contract awarded by the Department of Health and Human Services (HHS) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles, for the development of "small hollow nanodelivery vehicles for cancer treatment." The fixed-price contract has a ceiling value of $200,000.00 and a period of performance ending on March 30, 2010. Nanocomposix has previously performed prime contracts and subcontracts for...